2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Pathology, Serologic Tests, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Apoptosis, Pathogenesis, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, GVHD, Neutropenia, Infectious Diseases, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

5857 High-throughput single-cell cloning of multiple anti-HLA alloreactive TCRs

Jiaqi Zhang, MS, Jonah Sonnabend, MS2, Alexander M Rowe, PhD3, Wenzhong Wei, PhD4, Aashia Kataria5, Kevin Quann, MD, PhD6, Warren Shlomchik, MD7, Sawa Ito, MD, PhD8
1 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
2 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
3 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
4 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
5 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
6 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
7 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
8 University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Background: Alloreactive T cells play central roles driving graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects following allogeneic stem cell transplantation. However, the mechanisms of T cell receptor (TCR) recognition of mismatched human leukocyte antigen (HLA) are incompletely understood, at least in part due to technical challenges in cloning and tracking alloreactive TCRs. We applied the TCXpress (Ito et al.  Blood Adv. 2026;10(4):1114), high-throughput platform to clone TCRs from human CD8 cells responding to HLA-mismatched antigen-presenting cells.

Methods: Alloreactive T cells were generated using a mixed lymphocyte reaction (MLR), in which CD8? responder T cells (HLA-A*01:01,11:01, B*15:02, 37:01, C*06:02, 08:01) were co-cultured with B-lymphoblastoid cell lines (LCLs), with HLAs homozygous for A*02:01, B*15:01, and C*03:04. The activated T cells, defined by high CD25 expression and CellTracer Violet dilution, were single-cell index-sorted, and paired TCR-αβ sequences were cloned directly into lentiviral vectors using TCXpress via Gibson assembly. Bacteria were transformed with DNA from each Gibson assembly, and DNA was isolated from the bulk broth without picking single colonies. This DNA was used for lentivirus production and initial functional screening. TCR-encoding lentivirus were used to infect TCRαβ-knockout CD8a Jurkat cells. These Jurkat cell lines were co-cultured with the original stimulator cells and, as a negative control, against lymphoblasts generated from the responding T cell donor.  Alloreactivity was assessed by induction of CD69 on the TCR-transduced Jurkat cells. DNAs from TCRs that directed Jurkat alloreactivity were transformed into bacteria. Single colonies were picked, and DNA from each was used to create lentivirus, followed by transduction of Jurkat cells and testing for alloreactivity (“molecular deconvolution”).

Results: Based on clonality and cDNA quality, 73 TCRs were selected for plasmid generation, and 16 were functionally screened. Six TCRs demonstrated specific reactivity to original stimulator LCLs, with no response to autologous or control LCLs at bulk plasmid screening. After molecular deconvolution to clone single αβ chain pair-derived TCRs, two TCRs (TCR 402 and 798) were confirmed to be alloreactive against HLA-B*15:01-expressing LCLs, and one TCR (TCR 1018) was alloreactive against HLA-C*03:04-expressing LCLs.

Conclusions: These results demonstrate the feasibility of  cloning and functional validation of anti–HLA-specific alloreactive TCRs from single cells using TCXpress technology. Ongoing studies are validating alloreactivity using engineered antigen-presenting cells that express single HLA molecules. Ultimately, these TCRs can be used to identify their cognate peptides and generate HLA-peptide multimers to track alloreactive T-cell dynamics and elucidate their mechanistic roles in GVHD and GVL.

 

Jiaqi Zhang, MS: No relevant conflicts of interest to declare.